Relief Therapeutics Holding AG (RLFTF)

[GreenKnight]

$RLFTF DD Post on Bachem, Nephron, and mystery distributor.

But they also say this:

“"In normal circumstances, it would be prudent to wait until all the data are in before initiating commercial scale-up. However, in an environment where more than 40,000 Americans are contracting COVID-19 daily and 800 are dying each day, there is not a moment to lose in ensuring that sufficient quantities of RLF-100™ will be available, should the clinical trials succeed in proving safety and efficacy," said Dr. Jonathan Javitt, CEO and Chairman of NeuroRx, Inc.”


So IMO that tells me this is going to move VERY fast here in the US.

And then there is this sexy “mystery” puzzle piece here which I am excited about:

[B]NeuroRx and Relief have additionally contracted with a leading nationwide pharmaceutical logistics partner in order to ensure overnight supply to US hospitals, should RLF-100™ continue to succeed in clinical trials.[/B]


And then there is mention of Bachem Technologies[/B] which has assisted with the drug for 20years: https://www.bachem.com

Bachem Americas is a subsidiary of Bachem Holdings (trades on Swiss as “BANB”) [B]$2.7bln Market Cap[/B] :

“NeuroRx and Relief have similarly contracted with Bachem Americas (www.bachem.ch) to manufacture sufficient RLF-100TM drug substance to treat 1 million patients. Bachem was the first peptide manufacturer to synthesize RLF-100TM and has played a leading role in the development of the drug substance over the past 20 years.”

AND we have mention of Nephron Pharma in South Carolina:

https://www.bloomberg.com/profile/company/0193327D:US

Nice note on NEPHRON and what they have been doing in Respiratory Medicine and ALSO I see they have been producing “pre-filled syringes and IV bags” .... Sounds right in line with RLFTF’s potential IV treatments...


“Nephron 503B Outsourcing is a division of Nephron Pharmaceuticals Corporation. [B] This division produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. [/B] In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration as a sterile manufacturer of generic respiratory medications along with an Outsourcing Facility providing equal sterility and quality. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.